DaVita HealthCare Partners Inc. Hits New 52-Week High at $66.15 (DVA)
Shares of DaVita HealthCare Partners (NYSE:DVA) hit a new 52-week high during trading hours on Thursday, American Banking & Market News reports. The company traded as high as $66.15 and last traded at $65.60, with a volume of 896,195 shares trading hands. The stock had previously closed at $65.44.
DVA has been the subject of a number of recent research reports. Analysts at Zacks reiterated a “neutral” rating on shares of DaVita HealthCare Partners in a research note to investors on Tuesday. They now have a $68.00 price target on the stock. Separately, analysts at Raymond James upgraded shares of DaVita HealthCare Partners from a “market perform” rating to an “outperform” rating in a research note to investors on Monday. Finally, analysts at KeyCorp initiated coverage on shares of DaVita HealthCare Partners in a research note to investors on Tuesday, December 17th. They set a “buy” rating on the stock. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and six have given a buy rating to the stock. DaVita HealthCare Partners has a consensus rating of “Hold” and an average target price of $101.33.
DaVita HealthCare Partners (NYSE:DVA) last released its earnings data on Tuesday, November 5th. The company reported $0.98 earnings per share for the quarter, beating the analysts’ consensus estimate of $0.96 by $0.02. The company had revenue of $3.00 billion for the quarter, compared to the consensus estimate of $2.93 billion. During the same quarter last year, the company posted $1.56 earnings per share. DaVita HealthCare Partners’s revenue was up 54.2% compared to the same quarter last year.
DaVita HealthCare Partners Inc, formerly DaVita Inc, is a provider of dialysis services in the United States for patients suffering from chronic kidney failure, also known as end stage renal disease (NYSE:DVA).
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.